<DOC>
	<DOCNO>NCT01240408</DOCNO>
	<brief_summary>This randomize , single-dose , open-label , two-period crossover study 16 healthy subject . The study consist two phase : Pre-randomization Randomization . The Pre-randomization phase two period : Screening Baseline . In Randomization Phase , subject randomize one two possible treatment sequence ( fed/fasted fasted/fed ) . In period , subject receive single capsule contain 10 mg lenvatinib either without standard breakfast . There 2-week washout treatment .</brief_summary>
	<brief_title>E7080 Food Effect Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Healthy , male female subject age great equal 18 year less equal 55 year old ; 2 . Body mass index ( BMI ) great 18 less equal 32 kg/m2 Screening ; 3 . All female must negative serum Bhuman chorionic gonadotropin ( BhCG ) test result negative urine pregnancy test result Screening Baseline . Females childbearing potential must agree use medically acceptable method contraception ( eg , abstinence , intrauterine device , doublebarrier method condom + spermicide condom + diaphragm spermicide , contraceptive implant , oral contraceptive vasectomise partner ) throughout entire study period 30 day study drug discontinuation . The subject exempt requirement postmenopausal woman ( define great age 50 least 12 month amenorrhea ) subject sterilize surgically otherwise prove sterile ( eg , bilateral tubal ligation surgery least 6 month prior dose , hysterectomy , bilateral oophorectomy surgery least 2 month prior dose ) . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 12 week prior dose must continue use contraceptive study 30 day study drug discontinuation ; 4 . Male subject partner woman childbearing potential must use , partner must use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , intrauterine device ( IUD ) start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day ( longer appropriate ) last dose study drug ) . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) ; 5 . Provide write informed consent ; 6 . Are willing able comply aspect protocol . 1 . Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematological , neurological , psychiatric disease abnormality know history gastrointestinal surgery could impact pharmacokinetics study drug ; 2 . A clinically significant illness within 8 week clinically significant infection within 4 week , dose ; 3 . Evidence organ dysfunction clinically significant deviation normal medical history ; 4 . History clinically significant drug food allergy presently experience seasonal allergy ; 5 . Evidence clinically significant deviation normal physical examination , vital sign , electrocardiogram ( ECG ) clinical laboratory determination Screening Baseline ; 6 . Clinically significant ECG abnormality include marked baseline prolongation QT/QTc interval ( eg repeat demonstration QTc interval great 500 msec ) , family history prolong QTc syndrome sudden death ; 7 . History drug alcohol misuse within 6 month prior Screening , positive urine drug test Screening Baseline ; 8 . Positive result Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV ) screen , positive syphilis screen ; 9 . Diagnosed acquire immune deficiency syndrome ( AIDS ) , test positive human immunodeficiency virus ( HIV ) ; 10 . Participated another clinical trial le 4 week prior dose currently enrol another clinical trial ; 11 . Consumed caffeinated beverage food within 72 hour prior dose ; 12 . Consumed grapefruit grapefruit contain beverage food within 72 hour prior dose ; 13 . Experienced weight loss gain great 10 % within 4 week dose ; 14 . Engaged heavy exercise ( great equal 1 hour/day 5 times/week ) less 2 week prior Baseline ( eg , marathon runner , weight lifter , etc . ) ; 15 . Received blood product within 4 week , donate blood within 8 week , donate plasma within 1 week , dose ; 16 . Hemoglobin level le 12.0 g/dL ; 17 . Used prescription drug within 2 week prior screen ; 18 . Taken overthecounter ( OTC ) medication within 2 week prior dose ; 19 . Any condition would make him/her opinion Investigator Sponsor , unsuitable study , opinion Investigator , likely complete study reason ; 20 . Inability tolerate venepuncture and/or venous access ; 21 . History depression , deliberate self harm suicidal ideation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>